- Home
- YI vs CLRB Comparison
YI vs CLRB Comparison
Compare YI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- CLRB
- Stock Information
- Founded
- YI 2010
- CLRB 2002
- Country
- YI China
- CLRB United States
- Employees
- YI N/A
- CLRB N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- CLRB Health Care
- Exchange
- YI Nasdaq
- CLRB Nasdaq
- Market Cap
- YI 64.4M
- CLRB 76.0M
- IPO Year
- YI N/A
- CLRB N/A
- Fundamental
- Price
- YI $0.63
- CLRB $1.86
- Analyst Decision
- YI
- CLRB Strong Buy
- Analyst Count
- YI 0
- CLRB 2
- Target Price
- YI N/A
- CLRB $21.00
- AVG Volume (30 Days)
- YI 111.3K
- CLRB 289.0K
- Earning Date
- YI 11-27-2024
- CLRB 11-18-2024
- Dividend Yield
- YI N/A
- CLRB N/A
- EPS Growth
- YI N/A
- CLRB N/A
- EPS
- YI N/A
- CLRB N/A
- Revenue
- YI $2,026,540,888.00
- CLRB N/A
- Revenue This Year
- YI $61.85
- CLRB N/A
- Revenue Next Year
- YI N/A
- CLRB N/A
- P/E Ratio
- YI N/A
- CLRB N/A
- Revenue Growth
- YI 0.38
- CLRB N/A
- 52 Week Low
- YI $0.55
- CLRB $1.82
- 52 Week High
- YI $2.34
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- YI 37.59
- CLRB 30.70
- Support Level
- YI $0.65
- CLRB $1.97
- Resistance Level
- YI $0.70
- CLRB $2.18
- Average True Range (ATR)
- YI 0.05
- CLRB 0.10
- MACD
- YI -0.01
- CLRB -0.01
- Stochastic Oscillator
- YI 11.59
- CLRB 8.11
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.